Endocrine Abstracts

Background: the treatment of individuals with type 1 diabetes (T1D) has significantly evolved in recent years. Therefore, with the aim of achieving glycaemic targets to prevent or slow down the progression of the disease and its complications, hybrid closed-loop systems (AID) have been developed. These systems integrate three components: a continuous real-time glucose monitor, a control algorithm and an insulin pump. The objective of this study is to analyse the glycaemic and inflammatory profile changes in patients after one year of using these systems.

Materials and methods: 19 patients who initiated treatment with a hybrid closed-loop system (Medtronic 780G 26%, Tandem-ControlIQ 26%, and Roche-Diabeloop 48%) since November 2019 were included in this study, where 74% had previously used insulin pumps. Blood samples were taken previous (T0) and after (at 3, 6, and 12 months) pump implantation for inflammatory and biochemical analysis.

Results: a significant increase in time in range (TIR) was observed from the first month, with significant differences at all time points compared to T0 (P<0.001). The coefficient of variation (CV) decreased significantly from T0 to 3 months, and this reduction was maintained until the one-year mark (P<0.001). Regarding to HbA1c, a decreasing trend was observed (P=0.025), as well as a decrease in blood glucose levels (P<0.001). Additionally, the same parameters were studied based on whether patients had had previous insulin pump experience or not, and significant differences in TIR were found between T0 vs 6 months and T0 vs 1 year. Regarding the inflammatory profile, measured by protein expression of IL-6 and CPR, no significant changes were observed.

Conclusion: Hybrid closed-loop systems are a valuable tool for optimizing management of T1D, improving glycaemic control and variability. However, further studies with larger patient cohorts are necessary to analyse the effect of those systems on patients’ inflammatory profile.